您的位置: 专家智库 > >

中国博士后科学基金(2012M512119)

作品数:4 被引量:21H指数:2
相关作者:杨纪华张冠中焦顺昌更多>>
相关机构:中国人民解放军总医院沈阳军区总医院更多>>
发文基金:中国博士后科学基金更多>>
相关领域:医药卫生更多>>

文献类型

  • 4篇中文期刊文章

领域

  • 4篇医药卫生

主题

  • 2篇细胞
  • 2篇细胞肺癌
  • 2篇小细胞
  • 2篇小细胞肺癌
  • 2篇化疗
  • 2篇非小细胞
  • 2篇非小细胞肺癌
  • 2篇肺癌
  • 1篇单抗
  • 1篇培美曲塞
  • 1篇联合化疗
  • 1篇联合化疗治疗
  • 1篇疗效
  • 1篇疗效观察
  • 1篇鳞状
  • 1篇鳞状细胞
  • 1篇化疗治疗
  • 1篇PEMETR...
  • 1篇SCLC
  • 1篇TREATM...

机构

  • 2篇沈阳军区总医...
  • 2篇中国人民解放...

作者

  • 2篇焦顺昌
  • 2篇张冠中
  • 2篇杨纪华

传媒

  • 1篇现代肿瘤医学
  • 1篇The Ch...
  • 1篇解放军医学院...
  • 1篇Oncolo...

年份

  • 1篇2017
  • 1篇2014
  • 2篇2013
4 条 记 录,以下是 1-4
排序方式:
培美曲塞单药或联合铂类治疗非小细胞肺癌86例分析被引量:9
2013年
目的研究培美曲塞单药或联合铂类治疗局部进展或复发转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及安全性。方法回顾性分析2008年12月-2011年5月解放军总医院经组织病理学证实的局部进展或复发转移的NSCLC患者86例接受培美曲塞(Pem)500 mg/m2d1单药化疗,或者培美曲塞500 mg/m2d1联合顺铂75 mg/m2d1或卡铂AUC=5 d1联合化疗,均21 d为1周期。所有患者治疗过程中均接受叶酸、维生素B12及地塞米松治疗。结果 86例中无完全缓解病例,部分缓解10例,稳定53例,进展23例,客观缓解率11.6%(10/86),疾病控制率73.3%(63/86),中位无疾病进展时间为7.3月,中位生存时间为14.6月,1年生存率为45.1%。主要不良反应为Ⅰ/Ⅱ度消化道反应和白细胞减少。结论培美曲塞单药或联合铂类治疗局部进展或复发转移的NSCLC疗效确切,耐受性好。
张冠中焦顺昌杨纪华
关键词:培美曲塞化疗
贝伐珠单抗联合化疗治疗非鳞状细胞非小细胞肺癌的疗效观察被引量:10
2013年
目的:观察贝伐珠单抗联合化疗治疗非鳞状细胞非小细胞肺癌的疗效和安全性。方法:回顾性分析2010年7月-2011年12月解放军总医院经组织病理学证实的局部进展或复发转移的非鳞状细胞非小细胞肺癌患者接受贝伐珠单抗联合化疗方案治疗的临床资料。贝伐珠单抗7.5mg/kg,每3周1次,联合多西他赛、培美曲塞或吉西他滨±铂类化疗。化疗2周期后按实体肿瘤疗效评价标准(RECIST)评价疗效,按美国癌症研究所制定的常见毒性判定标准(NCI-CTC)3.0版评价不良反应。结果:21例患者中无完全缓解病例,部分缓解4例,稳定13例,进展4例,客观缓解率19.0%(4/21),疾病控制率81.0%(17/21),中位无疾病进展时间为7.0月,中位生存时间为10.4月。与贝伐珠单抗相关的不良反应出血6例(28.6%),高血压1例(4.8%),主要为I、II度,III、IV度少见。结论:贝伐珠单抗联合化疗治疗进展或复发的非鳞状细胞非小细胞肺癌疗效确切,耐受性好。
张冠中杨纪华焦顺昌
关键词:联合化疗
Efficacy of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer patients during tyrosine kinase inhibitor treatment被引量:2
2017年
Objective We aimed to evaluate the efficacy and safety of pemetrexed combined with erlotinib/gefitinib in advanced non-small cell lung cancer(NSCLC) patients during tyrosine kinase inhibitor(TKI) treatment. Methods Thirty-two patients with advanced NSCLC were divided into two groups. Patients in the control group received continuous daily epidermal growth factor receptor tyrosine kinase inhibitor(EGFRTKI) treatment, and patients in the experimental group received continuous daily EGFR-TKI along with pemetrexed treatment, which was administered on day 1 at 500 mg/m2. Erlotinib(150 mg) or gefitinib(250 mg) was administered daily from day 1 to day 21, with a cycle of every 21 days. Dexamethasone, folic acid, and vitamin B12 were also administered during the treatment. The endpoint of the primary study was the disease control rate. Results The objective response rate was 21.9%(95% CI: 7.6% to 36.3%) in the control group, whereas the disease control rate was 84.4%(95% CI: 71.8% to 97.0%) in the experimental group. The median progression-free survival was 6.2(95% CI: 2.4 to 10.0). Grades 3 or 4 adverse effects of leucopenia(15.6%), neutropenia(12.5%), anemia(3.1%), and nausea or vomiting(3.1%) were found in the experimental group.Conclusion The administration of pemetrexed combined with erlotinib or gefitinib showed a higher efficacy in TKI-resistant NSCLC patients. Further, the adverse effects of this drug combination were well tolerated by the patients. Pemetrexed combined with TKI treatment might provide a satisfactory therapeutic strategy for advanced NSCLC patients after TKI treatment.
Guanzhong ZhangZhaozhe LiuTao HanXiaodong XieShunchang Jiao
Treatment of etoposide capsule combined with cisplatin or carboplatin in elderly patients with small cell lung cancer
2014年
We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer (SCLC). Methods: From October 2011 to November 2013, 32 elderly patients (71-79 years old) with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region (China) were enrolled in the research. The patients were administrated with lastet capsule 150-175 mg, dl-5, combined with cisplatin 20 mg/m^2 dl-3 or carbopiatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results:After treatments, 2 cases acquired complete response (CR), 19 cases acquired partial response (PR), 8 cases acquired stable disease (SD), and 3 cases had progression of disease (PD). The objective response rate was 65.6% (21/32), disease control rate was 90.6% (29/32). The median time of progression-free survival (PFS) was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of 1/11 leukopenia and gastrointestinal reaction were observed. Conclusion: Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC.
Guanzhong ZhangZhaozhe LiuTao HanFang GuoQingqing SunYanan GeYaling HanXiaodong Xie
关键词:CISPLATINCARBOPLATINELDERLY
共1页<1>
聚类工具0